A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance
Authors:
- 12 December 2022
- journal article
- research article
- Published by Elsevier in European Urology Focus
- Vol. 9 (3) , 447-454
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (HHSN261201200031I, P30 CA023074)
This publication has 11 references indexed in Scilit:
- Immunotherapy for Localized Prostate CancerUrologic Clinics of North America, 2020
- Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancerJournal for ImmunoTherapy of Cancer, 2020
- A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory MoleculesClinical Cancer Research, 2019
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate CancerJournal of Clinical Oncology, 2019
- A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance StudyEuropean Urology Focus, 2018
- Immunotherapy of Prostate Cancer: Facts and HopesClinical Cancer Research, 2017
- Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancerCancer Immunology, Immunotherapy, 2013
- Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesCancer Immunology, Immunotherapy, 2011
- Impact of Tumour Volume on the Potential Efficacy of Therapeutic VaccinesCurrent Oncology, 2011
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancerCancer Immunology, Immunotherapy, 2009